Is BIIB a Buy? What to Consider in 2026
Last updated July 2026
Short answer
The bull case for Biogen (BIIB) rests on Leqembi Alzheimer's ramp: Leqembi is the single biggest swing factor, with Q1 2026 worldwide in-market sales around $168 million, up roughly 74 percent year over year across the US, Japan, and China. Revenue (TTM) is ~$9.7B. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: The legacy MS business (Tecfidera, Tysabri) continues to decline against generics and biosimilars, and full-year 2026 total revenue is guided down a mid-single-digit percentage. Whether BIIB is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
Biogen is a Cambridge, Massachusetts biotechnology company built on neuroscience. Its historic core is multiple sclerosis (Tysabri, Tecfidera, Vumerity), and it co-developed the spinal muscular atrophy drug Spinraza with Ionis. Its growth story now centers on Leqembi, the Alzheimer's antibody it markets with partner Eisai, alongside newer rare-disease products Skyclarys (Friedreich's ataxia) and Qalsody (ALS). In 2026 it closed the roughly $5.6 billion acquisition of Apellis Pharmaceuticals, adding the retinal drug Syfovre for geographic atrophy and Empaveli for rare blood and kidney diseases. The investment picture is a classic biotech transition. Legacy MS sales face generic and biosimilar erosion (Biogen guides MS revenue excluding Vumerity down a mid-teen percentage in 2026) and total revenue is expected to fall a mid-single-digit percentage for the full year. Against that, Leqembi is scaling fast (Q1 2026 in-market sales up 74 percent year over year), and management is using acquisitions and cost discipline to defend earnings. The stock trades at a low double-digit forward earnings multiple, reflecting both the cheap valuation and the uncertainty over whether new launches can outrun the declining base.
What's the case for buying BIIB?
1. Leqembi Alzheimer's ramp
Leqembi is the single biggest swing factor, with Q1 2026 worldwide in-market sales around $168 million, up roughly 74 percent year over year across the US, Japan, and China. Real-world data showing about 78 percent of patients still on therapy at 18 months supports the durability of the franchise. Subcutaneous maintenance dosing (IQLIK) could broaden adoption if uptake and reimbursement continue to build.
2. Rare-disease and new-product portfolio
Skyclarys (Friedreich's ataxia) grew roughly 22 percent year over year to about $151 million in Q1 2026, and high-dose Spinraza was approved to defend the SMA franchise against competition. The Apellis deal adds Syfovre for geographic atrophy and Empaveli for PNH and rare kidney diseases, products that together generated roughly $689 million in 2025. These launches are the intended replacements for shrinking legacy sales.
3. Cost discipline and cash-funded M&A
Biogen has leaned on operating-expense reductions to protect earnings, delivering non-GAAP EPS of about $3.57 in Q1 2026, up double digits year over year despite roughly flat revenue. It funded most of the Apellis purchase with cash on hand plus modest bank debt, preserving flexibility. The strategy is to convert a mature cash-generating base into growth through selective dealmaking.
What are the risks to BIIB?
The legacy MS business (Tecfidera, Tysabri) continues to decline against generics and biosimilars, and full-year 2026 total revenue is guided down a mid-single-digit percentage. Leqembi faces direct competition from Eli Lilly's Kisunla and lingering questions about diagnostic access, infusion logistics, and payer coverage, so its ramp could disappoint. Large acquisitions like Apellis add integration and execution risk, and contingent value payments tied to Syfovre sales create uncertain future costs. Biotech pipelines carry binary clinical and regulatory outcomes, and a single trial failure or safety signal can move the stock sharply. The low valuation reflects genuine skepticism that new products can offset the eroding base fast enough.
How is BIIB valued? (as of MAY 2026)
Snapshot for BIIB as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (TTM): ~$9.7B
- Q1 2026 revenue: ~$2.5B (up ~2% YoY)
- Q1 2026 non-GAAP EPS: ~$3.57
- Market cap: ~$29B
- Forward P/E: ~12x
- Recent share price: ~$183
Biogen trades at a low double-digit forward earnings multiple, well below the drug-manufacturer industry median, reflecting a shrinking legacy base and turnaround uncertainty. Q1 2026 earnings beat expectations on cost discipline and Leqembi momentum, but management still guides full-year revenue down a mid-single-digit percentage. The valuation prices in doubt that new launches will outrun legacy erosion.
How do you decide if BIIB is a buy?
Rather than asking whether BIIB is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold BIIB indirectly through an index or sector ETF before adding more.
For the full picture, see the BIIB stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about BIIB against your real portfolio and see your actual exposure before deciding.
The bottom line on BIIB
The bottom line: Biogen's story right now is Leqembi Alzheimer's ramp, with revenue (ttm) at ~$9.7B. If you believe that narrative continues, the call is about sizing BIIB sensibly and checking overlap with what you own; if you doubt it (the risk: the legacy MS business (Tecfidera, Tysabri) continues to decline against generics and biosimilars, and full-year 2026 total revenue is guided down a mid-single-digit percentage.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
Build a basket around BIIB with Walnut
Use Biogen as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is BIIB a good stock to buy right now?
+
The case for Biogen right now is Leqembi Alzheimer's ramp, with revenue (ttm) at ~$9.7B. If you believe that thesis holds, BIIB is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is the legacy MS business (Tecfidera, Tysabri) continues to decline against generics and biosimilars, and full-year 2026 total revenue is guided down a mid-single-digit percentage. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does Biogen do?
+
Biogen is a Cambridge, Massachusetts biotechnology company built on neuroscience.
What are the main risks of BIIB?
+
The legacy MS business (Tecfidera, Tysabri) continues to decline against generics and biosimilars, and full-year 2026 total revenue is guided down a mid-single-digit percentage. Leqembi faces direct competition from Eli Lilly's Kisunla and lingering questions about diagnostic access, infusion logistics, and payer coverage, so its ramp could disappoint. Large acquisitions like Apellis add integration and execution risk, and contingent value payments tied to Syfovre sales create uncertain future costs. Biotech pipelines carry binary clinical and regulatory outcomes, and a single trial failure or safety signal can move the stock sharply. The low valuation reflects genuine skepticism that new products can offset the eroding base fast enough.
What does Biogen do?
+
Biogen is a biotechnology company focused on neuroscience and rare diseases. Its products span multiple sclerosis (Tysabri, Tecfidera), the Alzheimer's drug Leqembi (with Eisai), spinal muscular atrophy (Spinraza), Friedreich's ataxia (Skyclarys), and, after the 2026 Apellis acquisition, retinal and rare-blood conditions.
Is BIIB a good investment?
+
That depends on your goals and risk tolerance, and Walnut is not an investment adviser. BIIB is a turnaround story: it trades cheaply relative to peers, but its legacy revenue is declining and the thesis rests on Leqembi and newer products succeeding. Consider how much biotech and single-drug risk fits your portfolio.
Why is Biogen's revenue declining?
+
Its historic multiple sclerosis franchise faces generic competition for Tecfidera and biosimilar competition for Tysabri, and Spinraza faces newer SMA rivals. Biogen guides full-year 2026 total revenue down a mid-single-digit percentage, with MS products excluding Vumerity down a mid-teen percentage.
How important is Leqembi to Biogen?
+
Leqembi is the company's most important growth driver. Worldwide in-market sales were around $168 million in Q1 2026, up roughly 74 percent year over year. Biogen shares the economics with partner Eisai, and a subcutaneous maintenance version could widen adoption if reimbursement and uptake continue building.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell BIIB; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.